Loading
Nalu Bio
Nalu Bio is a San Francisco biotech that combines predictive and generative AI with organic chemistry. Its ECS Technology Platform designs novel compounds targeting the endocannabinoid system for non-addictive therapeutics. It also sells chemistry-derived, no-high cannabinoid ingredients to CPG and therapeutics companies. It raised a $12M Series A in February 2023, bringing total funding to roughly $13.5M including a 2021 seed round, and in 2024 partnered with PIPA on AI-enabled cannabinoid blends for CPG brands.
Funding
Every round, secondary, debt facility or acquisition involving Nalu Bio that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—